Liraglutide in Treatment of Diabetes Mellitus Type 2: Systematic Review and Bibliometric Analysis Over The Last Two Decades
| dc.Affiliation | October University for modern sciences and Arts (MSA) | |
| dc.contributor.author | Kamal, Manar Ahmed | |
| dc.contributor.author | Al-Arawi, Raneem Mahmoud | |
| dc.date.accessioned | 2022-03-06T07:56:04Z | |
| dc.date.available | 2022-03-06T07:56:04Z | |
| dc.date.issued | 2022-03 | |
| dc.description | SJR 2024 3.529 Q1 H-Index 174 | |
| dc.description.abstract | Background: Type 2 diabetes mellitus (T2DM) is a chronic progressivemetabolic disorder and liraglutide is one of the glucagon-like peptide-1(GLP-1) agonists that are used to decrease glucose levels in the blood andhelp in weight loss in patients with T2DM. Bibliometric analysis is one ofthe most common statistical methods used to evaluate the credibility,quality, and impact of scholarly work. Methods: We performed a systematic review and bibliometricanalysis over the last two decades (2000-2020) by search on theWOS database for studies published in the literature on June 2021 byusing relevant keywords ("Diabetes Mellitus, Type II") AND(Liraglutide). We extract the data of the most ten cited articles,journals, countries, and years. The bibliometric analysis wasperformed by HistCite software. Results: There are 2500 records entered the bibliometric analysis anddivided into 1813 articles and 687 reviews. The highest-cited paper was"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes". The LANCETwas the top-cited journal with a 7599 total global citation score (TGCS).Novo Nordisk AS and USA were the most cited institution, countries inorder, and with a top number of publication records. Among the most citedarticles, 2016 was the first global citation year score (n=9585), while 2020was the top in a number of publications records (n=310). Conclusion: Our bibliometric analysis provides both quantitative andqualitative analyses and gives insight on the citation frequency of top-citedarticles published in using liraglutide in the treatment of patients withdiabetes mellitus type 2 . | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=26203&tip=sid&clean=0 | |
| dc.identifier.citation | Kamal, M. A., & Al-Arawi, R. M. (2022). Liraglutide in treatment of diabetes mellitus type 2: Systematic review and bibliometric analysis over the last two decades. Metabolism, 128, 154997. https://doi.org/10.1016/j.metabol.2021.154997 | |
| dc.identifier.doi | https://doi.org/10.1016/j.metabol.2021.154997 | |
| dc.identifier.other | https://doi.org/10.1016/j.metabol.2021.154997 | |
| dc.identifier.uri | http://repository.msa.edu.eg/xmlui/handle/123456789/4865 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Saunders | en_US |
| dc.relation.ispartofseries | Metabolism: Clinical and Experimental;128:154997 | |
| dc.subject | Bibliometric Analysis | en_US |
| dc.subject | Citation | en_US |
| dc.subject | Type 2 Diabetes Mellitus | en_US |
| dc.subject | Liraglutide | en_US |
| dc.subject | Web of Science. | en_US |
| dc.title | Liraglutide in Treatment of Diabetes Mellitus Type 2: Systematic Review and Bibliometric Analysis Over The Last Two Decades | en_US |
| dc.type | Article | en_US |